NCT05184296招募中不适用
ExtraCorporeal Membrane Oxygenation in the Therapy for REfractory Septic Shock With Cardiac Function Under Estimated (ECMO-RESCUE): a Prospective, Multicenter, Non-randomized Cohort Study
Second Affiliated Hospital of Guangzhou Medical University1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2023年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- 30-day survival
研究概览
简要总结
The ECMO-RESCUE study is a prospective, multicenter, non-randomized, cohort study. In this study, we aimed to assessed whether VA-ECMO treatment can improve the 30-day survival rate of patients with sepsis-induced refractory cardiogenic shock.
详细描述
All patients who meet inclusion criteria and have no exclusion criteria are considered to be enrolled. During the period of study, the participants can decide whether to accept ECMO based on their personal conditions. If a patient is willing to accept ECMO treatment, we initiate VA-ECMO within 6 hours. Participants taking VA-ECMO during the period of study are referred to as cohort 1, and patients receiving only conventional therapy without ECMO belong to cohort 2. 30-day survival will be accessed to evaluate the survival benefit from ECMO therapy for sepsis-induced refractory cardiogenic shock.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 75 years.
- •Patients admitted into ICU and diagnosed as septic shock (sepsis-3.0)13, after adequate fluid resuscitation, high-dose vasoactive drug application [vasoactive inotropic score (VIS) > 120] and conventional therapy together with at least one of the following criteria: (1) sustained hypotension [mean arterial pressure (MAP) < 65 mmHg]; (2) persistent lactacemia (two consecutive values > 5 mmol/L with at least 30 min interval between samples), with non-decreasing trend on steady doses of inotropes and/or vasopressors; (3) persistent low mixed venous blood oxygen saturation (SvO2) (two consecutive values < 55% with at least 30 min interval between samples), with non-increasing trend on steady doses of inotropes and/or vasopressors. The above condition lasts more than 5 hours.
- •Rapidly deteriorating sepsis-induced myocardial impairment is defined by at least one of the following criteria: (1) rapidly deteriorating ventricular function (LVEF < 35%); (2) cardiac index (CI) < 2L/min/m2 (> 3 hr); (3) emerging refractory arrhythmia.
- •Informed consent provided by the patient or person with decisional responsibility.
排除标准
- •Cardiac dysfunction caused by other causes is excluded, such as acute myocardial infarction, chronic heart failure, congenital cardiac disease, myocardial effusion, moderate to severe aortic regurgitation, severe aortic coarctation and so on.
- •High suspicion of pulmonary embolism, tension pneumothorax or cardiac tamponade as a cause of shock.
- •Prolonged cardiac arrest (> 30 min) before ECMO, or CPR survivors remaining comatose.
- •Irreversible condition or meet the inclusion criteria for more than 12 hr.
- •Presence of active bleeding or anticoagulant contraindications.
- •Peripheral artery disease disabling insertion of outflow cannula to femoral artery.
- •Irreversible neurological pathology
- •Severe underlying condition with lift expectancy less than 1 year.
- •Special population, such as pregnancy, acquired immune deficiency syndrome (AIDS).
- •Patient included in another interventional clinical trial.
结局指标
主要结局
30-day survival
时间窗: From date of enrolled (D0) until date of death from any cause or day-30, whichever came first
survival rate at day-30
次要结局
- ICU survival rate(From date of enrolled (D0) until date of death from any cause or date of discharge from ICU, whichever came first, assessed up to 6 months)
- 6-month survival(From date of enrolled (D0) until the date of death from any cause or 6-month, whichever came first)
- quality of life for long-term survival(at 6-months)
- hospital survival(From date of enrolled (D0) until date of death from any cause or date of discharge from hospital, whichever came first, assessed up to 6 months)
- hospital length of stay (LOS)(From date of enrolled (D0) until the date of death from any cause or discharge from hospital, whichever came first, assessed up to 6 month)
- ICU length of stay (LOS)(From date of enrolled (D0) until the date of death from any cause or discharge from ICU, whichever came first, assessed up to 6 month)
- successful rate of ECMO weaning(From date of weaning off ECMO until the date of death or 24 hours after ECMO weaning, whichever came first)
- the number of days alive without CRRT, mechanical ventilation and vasopressor(between Day 0 and up to Day 30)
- long-term survivors' cardiac function(at day-30 and 6-month)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Treatment of Extracorporeal Membrane Oxygenation in Severe PoisoningExtracorporeal Membrane OxygenationMedicinal PoisonNCT05762029Affiliated Hospital of Nantong University60
招募中
不适用
ECMO Treatment of Children in China in the Past 10 YearsExtracorporeal Membrane OxygenationChild, OnlyNCT04709432Children's Hospital of Fudan University500
已完成
不适用
Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome (ARDS)NCT01470703Assistance Publique - Hôpitaux de Paris249
已完成
不适用
PRospective Multicenter Observational Study on Transfusion Practice in Vv-ECMO Patients: The PROTECMO StudyExtracorporeal Membrane Oxygenation ComplicationTransfusion Related ComplicationHemorrhageAnticoagulant-induced BleedingNCT03815773The Mediterranean Institute for Transplantation and Advanced Specialized Therapies656
已完成
不适用
Blood Management During ECMO for Cardiac SupportDeath, Sudden, CardiacHEART ARRESTShock, CardiogenicArrhythmias, CardiacHemorrhageEmbolismBlood TransfusionDisseminated Intravascular CoagulationVenous ThrombosisNCT03714048St Vincent's Hospital, Sydney561